Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Denali Therapeutics (DNLI) Free Cash Flow (2017 - 2026)

Denali Therapeutics has reported Free Cash Flow over the past 9 years, most recently at -$100.1 million for Q4 2025.

  • Quarterly Free Cash Flow fell 12.67% to -$100.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$422.1 million through Dec 2025, down 16.09% year-over-year, with the annual reading at -$422.1 million for FY2025, 16.09% down from the prior year.
  • Free Cash Flow was -$100.1 million for Q4 2025 at Denali Therapeutics, up from -$105.9 million in the prior quarter.
  • Over five years, Free Cash Flow peaked at -$43.1 million in Q2 2022 and troughed at -$132.0 million in Q1 2025.
  • The 5-year median for Free Cash Flow is -$79.0 million (2022), against an average of -$81.1 million.
  • Year-over-year, Free Cash Flow plummeted 3838.14% in 2021 and then soared 35.36% in 2024.
  • A 5-year view of Free Cash Flow shows it stood at -$68.5 million in 2021, then fell by 7.73% to -$73.8 million in 2022, then plummeted by 36.63% to -$100.9 million in 2023, then grew by 11.98% to -$88.8 million in 2024, then decreased by 12.67% to -$100.1 million in 2025.
  • Per Business Quant, the three most recent readings for DNLI's Free Cash Flow are -$100.1 million (Q4 2025), -$105.9 million (Q3 2025), and -$84.2 million (Q2 2025).